
Kiora Pharmaceuticals Secures U.S. Composition of Matter Patent, Expanding Protection of Anti-Inflammatory Compound KIO104
Kiora Pharmaceuticals Receives Composition-of-Matter Patent for KIO-104 Introduction Encinitas, California–(Newsfile Corp. – February 13, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of…